Results 111 to 120 of about 18,115 (178)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells

, 2018
Salvage chemotherapy for refractory metastatic colorectal cancer using trifluridine/tipiracil (FTD/TPI) and regorafenib has shown survival benefits.
Teiji Takechi, Hiroyuki Okabe, Nozomu Tanaka, Kenichi Matsuo, Fumio Nakagawa, Kazuaki Matsuoka   +5 more
core   +1 more source

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

Liver Cancer
Introduction: In the phase 3 RESORCE trial, regorafenib prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) whose disease progressed on prior sorafenib.
Yoon Jun Kim, Philippe Merle, Richard S. Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Masafumi Ikeda, Alessandro Granito, Gianluca Masi, René Gerolami, Sung Bum Cho, Chih-Hung Hsu, Yi-Hsiang Huang, Long-Bin Jeng, Do Young Kim, Shi-Ming Lin, Matthias Pinter, Guoliang Shao, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Kung-Kai Kuo, Yilei Mao, Yih-Jyh Lin, Kangshun Zhu, Philip Twumasi-Ankrah, Javeed Khan, Maria Awan, Kirhan Ozgurdal, Shukui Qin   +29 more
doaj   +1 more source

BAM15 Enhances Regorafenib Cytotoxicity in a Canine Osteosarcoma Cell Model

Osteosarcoma is an aggressive primary bone malignancy affecting both humans and dogs, and canine osteosarcoma represents a valuable comparative model for investigating novel therapeutic strategies.
Anna Raciborska, Bożena Obmińska-Mrukowicz, Klaudia Marcinkowska, Agnieszka Dolnicka, Agnieszka Śmieszek, Vibeke Fosse   +5 more
core   +1 more source

Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib

Scientific Reports
Previous studies demonstrated codon-specific KRAS mutation as a potential biomarker of resistance in metastatic colorectal cancer (mCRC). Our study aimed to evaluate the association of RAS status on survival in patients with mCRC treated with ...
Meng-Che Hsieh, Kun-Ming Rau, Kuang-Wen Liu, Chong-Chi Chiu, Chih-I Chen, Ling-Chiao Song, Hsin-Pao Chen   +6 more
doaj   +1 more source

AMPK Pathway Activation Markers in GBM: Expression Patterns and Clinical Associations in a Real-World Study. [PDF]

Int J Mol Sci
Ferrarini F, Del Bianco P, Corrà M, Talienti T, Mauceri M, Boso D, Romanazzi G, Bedeschi M, Caccese M, Padovan M, Guerriero A, Esposito G, Desideri I, Franceschi E, Gaviani P, Buglione di Monale E Bastia M, De Salvo GL, Fiorentino A, Tesei A, Mazza T, Lombardi G, Indraccolo S.   +21 more
europepmc   +1 more source

Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis. [PDF]

Cancers (Basel)
Rizzaro MD, Fanizzi C, Fiore G, Remore LG, Vecchio GD, Scagliotti E, Pratelli G, Borsa S, Navone SE, Bertorelli I, Sironi LE, Roda G, Marfia G, Caroli M, Locatelli M.   +14 more
europepmc   +1 more source

Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States. [PDF]

PLoS One
Denu RA, Appukkuttan S, Hocum B, Liao N, Katta A, Heo J, Schroader B, Singh R, Babajanyan S, Somaiah N.   +9 more
europepmc   +1 more source

The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. [PDF]

Clin Cancer Res
Cecchini M, Han SW, Lee S, Lee KW, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Khemka V, Wainberg ZA.   +14 more
europepmc   +1 more source

Comparing the Effectiveness and Safety of Different Third-Line Management Options for Patients with Metastatic Colorectal Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis. [PDF]

Cancers (Basel)
Abdelrahim M, Esmail A, Mustafa N, Al-Najjar E, Hamdaneh Y, Alabed Z, Abdel-Razeq H, Mansour A.   +7 more
europepmc   +1 more source

Efficacy and Safety of Regorafenib with or without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Systematic Review and Arm-Level Synthesis of Real-World Comparative Cohorts. [PDF]

Onco Targets Ther
Yu X, Zan H, Deng W, He R.
europepmc   +1 more source